Acarix As Stock Fundamentals
| ACARIX Stock | SEK 0.32 0.01 3.03% |
Acarix AS fundamentals help investors to digest information that contributes to Acarix AS's financial success or failures. It also enables traders to predict the movement of Acarix Stock. The fundamental analysis module provides a way to measure Acarix AS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acarix AS stock.
Acarix |
Acarix AS Company Shares Outstanding Analysis
Acarix AS's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Acarix AS Shares Outstanding | 373.33 M |
Most of Acarix AS's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acarix AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Acarix AS has 373.33 M of shares currently outstending. This is 106.79% higher than that of the Health Care Equipment & Supplies sector and 113.4% higher than that of the Health Care industry. The shares outstanding for all Sweden stocks is 34.71% higher than that of the company.
Acarix AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Acarix AS's current stock value. Our valuation model uses many indicators to compare Acarix AS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Acarix AS competition to find correlations between indicators driving Acarix AS's intrinsic value. More Info.Acarix AS is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Acarix AS by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Acarix AS's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Acarix Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acarix AS's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acarix AS could also be used in its relative valuation, which is a method of valuing Acarix AS by comparing valuation metrics of similar companies.Acarix AS is currently under evaluation in shares outstanding category among its peers.
Acarix Fundamentals
| Return On Equity | -1.46 | |||
| Return On Asset | -0.8 | |||
| Operating Margin | (13.75) % | |||
| Current Valuation | 51.77 M | |||
| Shares Outstanding | 373.33 M | |||
| Shares Owned By Insiders | 10.28 % | |||
| Shares Owned By Institutions | 2.84 % | |||
| Price To Book | 1.63 X | |||
| Price To Sales | 15.38 X | |||
| Revenue | 3.76 M | |||
| Gross Profit | 2.82 M | |||
| EBITDA | (48.28 M) | |||
| Net Income | (51.73 M) | |||
| Cash And Equivalents | 15.86 M | |||
| Cash Per Share | 2.24 X | |||
| Total Debt | 239 K | |||
| Debt To Equity | 2.30 % | |||
| Current Ratio | 7.38 X | |||
| Book Value Per Share | 0.20 X | |||
| Cash Flow From Operations | (48.01 M) | |||
| Earnings Per Share | (0.31) X | |||
| Target Price | 0.75 | |||
| Beta | 1.65 | |||
| Market Capitalization | 107.15 M | |||
| Total Asset | 118.6 M | |||
| Net Asset | 118.6 M |
About Acarix AS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acarix AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acarix AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acarix AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Acarix AB , a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases primarily in Europe, China, and the United States. Acarix AB was founded in 2004 and is based in Malm, Sweden. Acarix AB operates under Medical Devices classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Acarix Stock
Acarix AS financial ratios help investors to determine whether Acarix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Acarix with respect to the benefits of owning Acarix AS security.